Acute Phase Reactants and Complement Activation in Patients with Acute Myocardial Infarction

Complement ◽  
1988 ◽  
Vol 5 (1) ◽  
pp. 33-39 ◽  
Author(s):  
Tom E. Mollnes ◽  
Kari E. Tambs ◽  
Yngvar Myreng ◽  
Lars F. Engebretsen
Cardiology ◽  
2018 ◽  
Vol 141 (2) ◽  
pp. 88-97 ◽  
Author(s):  
Yan Gao ◽  
Yan Qiu ◽  
Jihua Wu ◽  
Wei Diao ◽  
Haibo Zhang ◽  
...  

Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising target for lowering plasma low-density lipoprotein cholesterol and preventing cardiovascular (CV) disease. Whether plasma PCSK9 measured during the acute phase predicts recurrent CV events in patients with acute myocardial infarction (AMI) remains unresolved. Methods and Results: Plasma PCSK9 levels were measured in 1,646 patients with AMI from the China PEACE-Prospective AMI Study at the acute phase. Additionally, 248 patients were resampled and measured at 1 month post-AMI. Associations of acute-phase PCSK9 tertiles with clinical characteristics and recurrent CV events within 1 year were assessed. Female gender (OR 1.94, 95% CI 1.24–3.03), premature coronary heart disease (CHD; OR 2.12, 95% CI 1.37–3.26), higher high-sensitivity C-reactive protein (OR 1.67, 95% CI 1.44–1.95), and higher triglycerides (OR 1.46, 95% CI 1.03–2.09) were associated with higher baseline PCSK9. Plasma PCSK9 levels in the highest tertile (versus lowest) did not have an increased risk of 1-year recurrent CV events in the AMI cohort (HR 0.78, 95% CI 0.52–1.16) or any subgroup. There was also no association between percentage changes in PCSK9 over the first month and 1-year recurrent events, although there was a trend of differences between patients in the upper versus lower tertiles. Conclusion: Plasma PCSK9 levels measured during the acute phase were associated with high-sensitivity C-reactive protein, triglycerides, premature CHD, and gender in patients with AMI but did not predict recurrent CV events within 1 year. Dynamic changes in PCSK9 suggested a trend yet no significance value in predicting recurrent CV events.


Author(s):  
J Delanghe ◽  
M De Buyzere ◽  
I De Scheerder ◽  
D Vogelaers ◽  
J Vandenbogaerde ◽  
...  

In the acute phase of acute myocardial infarction (3–8 h after onset of symptoms) an early transient increase in the creatine concentration of serum, saliva, and especially of urine can be observed. Due to the renal threshold, urine values give a much better discrimination between infarction patients and controls than do serum determination. In some patients secondary peaks of serum and urine creatine concentrations can be seen about 24–36 h after hospital admission. Intramuscular injections of 5·0 mL of a saline solution and muscular trauma interfere with the test, but with angina pectoris interference is absent or limited. Creatine leakage from myocardium is insufficient to explain the observed creatinuria in infarctions, and intact extra-cardiac tissues are believed to be involved in creatine release.


1993 ◽  
Vol 56 (SupplementV) ◽  
pp. 1409-1413
Author(s):  
Takeshi Motomiya ◽  
Yoshiki Tokuyasu ◽  
Harumizu Sakurada ◽  
Osamu Yanase ◽  
Shuzo Nomura ◽  
...  

2008 ◽  
Vol 33 (3) ◽  
pp. 98-102 ◽  
Author(s):  
ASM Giasuddin ◽  
Jamila M ElMahdawi ◽  
Fakhri M ElHassadi

Serum complement (C3, C4) levels in Libyan patients with acute myocardial infarction (AMI; 31 patients) and angina pectoris (AP; 11 patients) at the 1st day and 7th day of attack were estimated. A group of 26 healthy Libyans were taken as control subjects (CS). Serum C3 and C4 levels (mean ± SD, mg/dl) were elevated at the 1st day in AMI as well as AP patients (C3 → AMI1: 154.0 ± 28.5, AP1: 152.0 ± 45.0, CS: 132.0 ± 8.0, ANOVA: p=0.0072; C4→ AMI1: 38 ± 13, AP1: 37 ± 17, CS: 29 ± 6, ANOVA: p=0.0160). No significant differences for the elevated C3 and C4 levels at the 1st day were observed between the two diseases groups (AMI1 vs AP1 → C3: p=0.879, C4: p=0.818). At the 7th day, C3 and C4 levels were further elevated in AMI, while they remained at the similar elevated levels in AP (C3 → AMI 7: 173.1 ± 28.0, AP 7: 149.0 ± 41.0, CS: 132.0 ± 8.0, ANOVA: p=0.0000; C4 → AMI 7: 46.0 ± 7.0, AP 7: 36.0 ± 15.0, CS: 29.0 ± 6.0, ANOVA: p=0.0000). Again, no significance differences for the raised C3 and C4 levels at the 7th day was observed between AMI and AP patients (AMI 7 vs AP 7 → C3: P=0.059, C4: p=0.06). The C3 elevation showed significant positive correlation in AMI group (r=0.522, p=0.003) while it was insignificant in AP patients (r=0.037, p=0.915). Regarding C4 levels, it was significantly correlated in AMI (r=0.483, p=0.006), and in AP, although it was positively correlated (r=0.656, P=0.028) the observed difference was not significant (t=0.29, p=0.778). In conclusion, serum C3 and C4 levels were more profoundly elevated in AMI compared to AP patients suggestive of an acute phase and inflammatory response.DOI = 10.3329/bmrcb.v33i3.1141Bangladesh Med Res Counc Bull 2007; 33: 98-102


Sign in / Sign up

Export Citation Format

Share Document